ArticleBMC nephrology2026
Biopsy-confirmed Mycobacterium kansasii peritonitis with CT peritoneography in a young PD patient: a case report.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMycobacterium kansasii is an exceptionally rare cause of peritoneal dialysis (PD)-related peritonitis and may present with subtle, indolent features that delay recognition. This case illustrates how "silent" atypical peritonitis can be unmasked by pairing contrast-enhanced computed tomography (CT) with CT peritoneography: the former identified nodular biopsy targets, while the latter revealed loculated dialysate flow and failure of free intraperitoneal circulation. CASE PRESENTATION: A 20-year-old male had received automated PD for 3 years and was being evaluated for combined heart-kidney transplantation because of severe cardiomyopathy. He presented with vague abdominal discomfort, declining ultrafiltration, mild pedal edema, and weight loss. PD effluent (PDE) showed mononuclear-predominant leukocytosis (49-150 cells/µL), but repeated PDE cultures, AFB staining, and molecular testing were negative. Contrast-enhanced CT revealed multiple peritoneal nodules and omental stranding; CT peritoneography exposed a trapped contrast-containing pocket, providing functional evidence of impaired dialysate circulation. Ultrasound-guided biopsy showed necrotizing granulomatous inflammation, and tissue culture subsequently grew M. kansasii with rifampicin resistance. Because the isolate was also resistant to moxifloxacin and ciprofloxacin, fluoroquinolone-based therapy was avoided. Guided by susceptibility testing, we treated him with isoniazid, azithromycin, ethambutol, and amikacin, and the PD catheter was removed for refractory atypical mycobacterial peritonitis with progressive catheter dysfunction, prompting transition to hemodialysis. Symptoms and inflammatory markers resolved within 6 weeks; however, antimycobacterial therapy was curtailed at 165-179 days when the patient sustained an out-of-hospital sudden cardiac arrest of undetermined cause, in the setting of his severe underlying cardiomyopathy.
conclusionsThis case adds to the limited literature on M. kansasii PD peritonitis and describes an imaging-guided diagnostic pathway in which contrast-enhanced CT localized peritoneal lesions, CT peritoneography demonstrated impaired dialysate circulation, and targeted biopsy enabled tissue diagnosis. Susceptibility-guided therapy and catheter removal were followed by clinical control of the infection, although definitive cure could not be established because follow-up ended with the patient's death. As a single case, these observations are hypothesis-generating and should not be interpreted as establishing diagnostic criteria or standard management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.